A STATISTICAL APPROACH TO DEVELOPMENT OF TASTE MASKED EFFERVESCENT TABLETS OF SILDENAFIL CITRATE CONTAINING KYRON T134

NISHANT OZA*, SWATI SAGAR, AKRUTI KHODAKIYA, ASIT SAHU
C. U. Shah College of Pharmacy and Research, Wadhwan City, Gujarat, India
Email: ozanishant@gmail.com

Received: 25 Mar 2020, Revised and Accepted: 14 May 2020

ABSTRACT

Objective: The aim of present work was to mask the bitter taste of sildenafil citrate by preparing drug resin complex (DRC) and develop sildenafil citrate 100 mg effervescent tablets.

Methods: Sildenafil citrate and kyron T134 complexes were prepared at different conditions and evaluated for taste and drug loading. Optimized DRC was used to formulate the dispersible tablet by direct compression technique. A 3² full factorial design was used to study the effect of effervescent agent (X₁) and croscarmellose sodium (X₂) on dispersion time (Y₁) and wetting time (Y₂). Factorial batches were also evaluated for thickness, hardness, content uniformity, friability, in vitro drug release and stability studies. Multiple linear regression analysis, ANOVA and graphical representation of the influence factor by 3D plots were performing by using sigma plot 11.0. A Check point batch was design according to the results of desirability value and evaluated for all the parameter

Results: FT-IR study confirm that sildenafil citrate and kyron T134 were compatible with each other. Among the various DRC batch B29 was found with less bitter and give a more drug loading. Checkpoint batch showed no significance difference between predicted value and actual value for dispersion time and wetting time and it was found stable during stability study.

Conclusion: Sildenafil citrate bitter taste was masked by kyron T134 and full factorial design result was indicate that independent variables have significant effect on dependent variables

Keywords: Taste masking, Ion-exchange resin, Sildenafil citrate, Dispersible tablet, 3² full factorial design, kyron T134

INTRODUCTION

Oral route of drug administration is the most appealing route for the drug delivery but the numbers of orally administered drugs are bitter taste and that creates an unpleasant feeling in the mouth. Therefore, it is necessary to mask the bitterness for enhancing patient acceptability [1, 2]. Ion exchange resins are inexpensive and used to develop a simple, rapid and cost-effective method of taste masking. Ion exchange resins are cross-linked polymers containing salt forming groups in repeating positions on the polymer chain, have an affinity for oppositely charged counter ions, thus adsorbing the ions into the polymer matrix. For immediate release purpose, several ion-exchange resins have been developed for oral administration. Kyron T134 is a derivative of cross-linked polyacrylic polymer used to mask the bitter of medicines. It is also a weak acid derivative of acrylic acid cross-linked polymer having carboxylic acid functional group, which contains K⁺ionic form [3, 4].

Sildenafil citrate, a selective inhibitor of phosphodiesterase type 5 enzymes (PDE5) and it is used for the treatment of erectile dysfunction. It has extreme bitter taste resulting in poor patient compliance. Conventional sildenafil citrate tablets available in market are not suitable when quick onset of action is required. It needs to be taken before at least 30 min for the desired action due to slow release of the drug. Thus, effervescent tablet can potentially achieving rapid onset of desirable action in a convenient manner [5, 6].

The present work was carried out to develop sildenafil citrate 100 mg effervescent tablets, which will mask the bitter test of drug with ion-exchange resin and make the immediate release formulation for quick onset of action.

MATERIAL AND METHODS

Materials

Sildenafil citrate was received as a generous gift from Phanicare chemicals, Hyderabad, India. Kyron T134 was obtained from Corel pharma chem., Ahmedabad, India. Croscarmellose sodium was purchase from Madhu hydrocolloids Pvt. Ltd., Ahmedabad. All other materials and chemicals used were of either pharmaceutical or analytical grade.

Drug-excipients compatibility study

Drug-excipients interaction plays a vital role in achieving stability of drug in dosage form. Fourier transform infrared spectroscopy (FT-IR) was used to study the physical and chemical interactions between drug and excipients. DSC and FT-IR spectra of sildenafil citrate, kyron T134 and DRC were obtain by using FT-IR instrument. (FT-IR-1700, Shimadzu, Kyoto, Japan). Thermograms of sildenafil citrate and drug-excipients physical mixture were obtain by using an automatic thermal analyzer system (DSC 60, Shimadzu, Japan). The analysis was performed at a rate of 20 °C/min from 50 °C to 300 °C under a nitrogen flow of 25 ml/min [7, 8].

Development and evaluation of drug resin complex (DRC)

In batch process drug resin complex was develop using different process variables. In this process, activated resin was placed in a beaker that containing deionized water. Different ratio of sildenafil citrate and kyron T134 was add and stirred for different periods at various pH as shown in table 3. Batch B1 to B4 was contained sildenafil citrate with different ratio of kyron T134 and stirred for 240 min. Then, the mixture was filter and residue was wash with deionized water. For an optimization DRC was prepared at different pH, temperature, soaking time of resin and stirring time. Batch B5 to B12 was developed at various pH. Batch B13 to B17 was prepared at 40 °C, 50 °C, 60 °C, 70 °C and 80 °C. Batch B18 to B25 was prepared to check the effect of soaking time on drug loading. Using previously optimized conditions batch B26 to B32 was prepared to check the effect of stirring time on drug loading [9, 10]. All batches were evaluated for taste and % of drug loading.

Prepared DRC taste evaluation was done by a panel of 6 volunteers in the age group of 20 to 25 y using time intensity method. Each
volunteer held equivalent to 100 mg sildenafil citrate in the mouth and bitterness were record up to 1 min against pure drug. The yield of DRC was calculated using following equation.

In vitro drug release of optimized batch DRC was determined using a USP XXIV type II dissolution apparatus. Drug equivalent to 100 mg DRC was add in 900 ml 0.01 M HCl and maintained at 37 °C. Sample was withdrawn at definite time interval and the amount of drug was estimated spectrophotometrically at 292.5. Drug release from the DRC was also performed in deionized water by repeating same procedure [11, 12].

Preliminary trail of sildenafil citrate 100 mg effervescent tablets

Direct compression technique was use to develop sildenafil citrate 100 mg effervescent tablets. Preliminary trail of effervescent tablets were prepared as described in table 1. Preliminary trail batch was prepared to check the effect of effervescent agent and croscarmellose sodium on dispersion time and wetting time. As an effervescent agent Citric acid: Tartaric acid: Sodium bicarbonate (1: 2: 3.44) was taken. All the raw materials were passed through sieve no. 40 and it was mixed in a geometrical order for 15 min. Aerosol, Talc and magnesium stearate were add before compression. Compression was carry out using flat round shape punch. At the time of manufacturing of effervescent tablets, humidity and temperature was maintained at 25 % RH and 25 °C respectively [13, 14].

| Ingredients          | T1 Quantity in mg | T2 Quantity in mg | T3 Quantity in mg | T4 Quantity in mg | T5 Quantity in mg | T6 Quantity in mg | T7 Quantity in mg |
|----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| DRC                  | 242              | 242              | 242               | 242               | 242               | 242               | 242               |
| Effervescent agent   | 0.15             | 0.15             | 0.15              | 0.15              | 0.15              | 0.15              | 0.15              |
| Croscarmellose sodium| 22.5             | 22.5             | 22.5              | 22.5              | 22.5              | 22.5              | 22.5              |
| Betacyclodextrin      | 462              | 462              | 462               | 462               | 462               | 462               | 462               |
| Lactose: Mannitol      | 18              | 18               | 18                | 18                | 18                | 18                | 18                |
| Sucrose              | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Dry orange flavor    | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Sunset yellow Color  | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Aerosil              | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Talc                 | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Magnesium stearate   | 45               | 45               | 45                | 45                | 45                | 45                | 45                |
| Total                | 1500             | 1500             | 1500              | 1500              | 1500              | 1500              | 1500              |

*Drug resin complex (DRC) contain Sildenafil citrate 100 mg and kyron T134, #effervescent agent = Citric acid: Tartaric acid: Sodium bicarbonate (1: 2: 3.44)

Evaluation of sildenafil citrate 100 mg effervescent tablets

Bulk density, Tapped density, Carr’s index, Angle of repose, Average weight, Thickness, Hardness, Weight variation and % Friability of the effervescent tablets were measured as described by Yadav K et al., Khar RK et al., Madgulkar AR et al., and Lakade SH et al., respectively [15-18].

Dispersion time: Dispersion time was measured by dropping a tablet in a measuring cylinder containing 6 ml of deionized water. The time for the tablet to completely disintegrate into fine particles was noted. Six tablets from each batch were randomly selected and dispersion time was recorded.

Wetting time: It was measure by using five circular tissue papers of 10 cm in diameter, which was place in a petridish of 10 cm diameter. 10 ml of eosiin solution was adding to the petridish. A tablet was carefully place on the surface of the tissue paper. The time for complete wetting was noted and recorded as the wetting time.

In vitro drug release of effervescent tablets was determined using USP XXIV type II dissolution apparatus at 100 rpm. A tablet was add to 900 ml 0.01 M HCl for 30 min at 37 ± 0.5 °C. At predetermined time intervals, 10 ml of the sample was collect and replaced with the same volume of fresh medium. Solution was dilute and assay at 292.5 nm using a UV-Vis double beam spectrophotometer.

Taste evaluation test performed by a panel of ten volunteers. The volunteers selected randomly and instructed to rate the samples as per the taste evaluation scale [19-20].

Optimization of excipients amount by using 3^2 full factorial design

A 3^2 full factorial design was use in the present study. Formulation of factorial batches was show in table 2. On the basis of preliminary results, the amount of effervescent agent (X1) and amount of croscarmellose sodium (X2) were chosen as independent variables in 3^2 factorial design, while dispersion time (DT) and wetting time (WT) were taken as dependent variables. Multiple linear regression analysis, ANOVA and graphical representation of the influence of factor by contour plots were perform using sigmaplot 11.0. The experimental runs and measured responses of 3^2 full factorial design batches of sildenafil citrate 100 mg dispersible tablets were deplete in table 7 [21-25].

| Ingredients          | Quantity in mg |
|----------------------|----------------|
| DRC                  | 242            |
| Effervescent agent   | 0.15           |
| Croscarmellose sodium| 22.5           |
| Lactose: Mannitol    | 18             |
| Sucrose              | 45             |
| Dry orange flavor    | 45             |
| Sunset yellow Color  | 45             |
| Aerosil              | 45             |
| Talc                 | 45             |
| Magnesium stearate   | 45             |
| Total                | 1500           |

*Drug resin complex (DRC) contain Sildenafil citrate 100 mg and kyron T134, #effervescent agent = Citric acid: Tartaric acid: Sodium bicarbonate (1: 2: 3.44)
Stability study of sildenafil citrate effervescent tablets

Optimized batch was packed in aluminum foil and was placed for stability study at 40°C/75% RH for 3 mo. Sample was evaluated after 3 mo for physical parameters and in vitro dissolution. The dissolution profile of product was compared using similarity factor, $f_2$, which was calculated by following formula:

$$f_2 = 50 \log \left[ \left(1 + \frac{1}{n} \sum (R_t - T_t)^2 \right)^{1/2} \cdot 100 \right]$$

where $\log$ is logarithm to the base 10, $n$ is the number of time points, $\sum$ is summation over all time points, $R_t$ is the mean dissolution value of the reference profile at time $t$, and $T_t$ is the mean dissolution value of the test profile at the same time point. The USFDA draft guidance document contains more information on similarity factor ($f_2$). The value of similarity factor ($f_2$) between 50 and 100 suggests that the two dissolution profiles are similar [24-26].

RESULTS AND DISCUSSION

The powder characteristics of sildenafil citrate like angle of repose, Hausner’s ratio and Carr’s index showed that drug is poorly compressible and have poor flow properties. So in present study, directly compressible excipient were selected which improved flow property, compressibility and also gives desired drug release.

Drug excipients compatibility study

IR spectra of sildenafil citrate, kyron T134 and DRC are show in fig. 1. The IR spectrum of DRC was found to exhibit some significant difference in the characteristic peaks of sildenafil citrate, revealing modification of the drug environment. As shown in the fig. 1 (A), a peak was observed at 3299 cm$^{-1}$. IR spectra of DRC showed in fig. 1 (C) shifting of peak this peak from 3299 to 3309 cm$^{-1}$. Shifting of this peak suggests the formation of new N-H stretching which was previously absent in pure drug. This shows the formation of complex of drug with resin. Thermogram of DSC of sildenafil citrate, kyron T134 and DRC are show in fig. 2. Thermogram of sildenafil citrate showed endothermic peak at 188.2°C whereas DRC showed endothermic peak at 188.2°C. Therefore, there was negligible change in the melting peak of sildenafil citrate. Therefore, it was confirm that sildenafil citrate and kyron T134 were compatible with each other [27, 28].

![Fig. 1(A): Infrared spectra of sildenafil citrate](image1)

![Fig. 1(B): Infrared spectra of kyron T134](image2)
Optimization of drug resin complex (DRC) using different process variables

Drug resin complex was developed by using different process variables. Batch B1 to Batch B4 was prepared by varying the ratio of sildenafil citrate to kyron T134 and drug loading efficiency and bitterness level was observed. From the results, it was clearly revealed that drug loading increases with an increase in drug resin ratio. There was no significant difference in drug loading as well as taste, when drug: resin ratio was changed from 1:2 to 1:3 and 1:4. Therefore, the drug-resin ratio of 1:2 was used to check the effect of pH on drug loading. pH was shown significantly change on drug loading efficiency. There was no change in drug loading when pH was changed from 7 to 9. So, the deionized water used as a medium for further optimization. Here, the effect of temperature on drug loading was measured using drug: resin ratio 1:2 and pH 7. Results showed that there was no significant change in drug loading efficiency on change in temperature. So 30 °C was selected for further study. Batch B19 to B25 was prepared to show drug loading increases with soaking time up to 30 min. There was no significant difference was observed, when soaking time was changed from 30 min to 120 min. Thus, the 30 min soaking time was used as optimized time for obtaining maximum drug loading. Batch B26 to B32 was prepared to check the effect of stirring time. The results showed that above 240 min drug loading was not increase. Therefore, batch B29 was used for further studies to prepare sildenafil citrate dispersible tablet.
In this study, sildenafil citrate release from drug resin complex was observed in 0.01 M HCl and deionized water separately. In 0.01 M HCl, more than 90% of drug was release within 2 min, whereas in deionized water, less than 15% drug was released within 20 min. In vitro drug release from DRC in deionized water was negligible indicating potential application in effervescent tablets. In addition, drug release of almost 100% within 4 min in 0.01 M HCl is favorable for effervescent tablets.

Table 4: Preliminary trial batch evaluation of sildenafil citrate 100 mg effervescent tablets

| Batch | Dispersion time(s) | Wetting time(s) |
|-------|--------------------|----------------|
| T1    | 160.66±2.51        | 43.13±1.15     |
| T2    | 97.33±1.52         | 28.66±0.57     |
| T3    | 89.66±2.08         | 24.33±0.57     |
| T4    | 85.33±1.52         | 21.66±1.15     |
| T5    | 78.33±1.15         | 18.33±0.57     |
| T6    | 74.33±0.57         | 15.33±0.57     |
| T7    | 113.33±1.52        | 34.66±0.57     |

(n=6)
Preliminary trial batch evaluation of sildenafil citrate 100 mg dispersible tablets

In vitro dispersion time and wetting time of preliminary batches were determined to check the effect of effervescence agents and croscarmellose sodium. From results shown in Table 4, it was clear that amount of effervescence agents and croscarmellose sodium showed significant effects on dispersion time and wetting time of the effervescence tablets. An increase in the amount of effervescence agents and croscarmellose sodium showed significant decrease in dispersion time and wetting time of the tablets. Hence, amount of effervescence agents and croscarmellose sodium were select as optimize factors for sildenafil citrate 100 mg effervescence tablets. In batch T1, only super disintegrant was use to formulate the tablets without using effervescence agents that showed very high dispersion time and wetting time. This clearly indicates that effervescence agents had the significant effects on both dispersion time and wetting time. Therefore, an effervescence agent was taking as one of the factor for the effervescence tablets. Batch T7 was formulated by using only effervescence agents without super-disintegrant. The results showed increased in vitro dispersion time and wetting time. This suggests that super-disintegrant significantly affects the in vitro dispersion time and wetting time. Therefore, super-disintegrant was select as another factor for the effervescence tablets. In a preliminary trial batches β-cyclodextrin was use to improve the solubility of the drug. However, the drug solution did not allow the drug to dissolve in deionized water. The sildenafil citrate and kyon T134 complex was already showed significant drug release in gastric pH. Therefore, β-cyclodextrin was not use in the formulation of full factorial batches.

### Table 5: Factorial batch evaluation of sildenafil citrate 100 dispersible tablets

| Batch | Bulk density (g/ml) | Tapped density (g/ml) | Carr’s index (%) | Angle of repose (θ) | Average weight (mg) | Thickness (cm) | Hardness (kg/cm²) | Friability (%) | Content uniformity (%) |
|-------|---------------------|----------------------|------------------|-------------------|---------------------|---------------|------------------|---------------|-----------------------|
| F1    | 0.7±0.02            | 0.83±0.01            | 14.25±1.18       | 28.61±0.23        | 150.4±5.46         | 2.69±0.02     | 3.32±0.27        | 0.73±0.04     | 101.6±0.75            |
| F2    | 0.68±0.05           | 0.80±0.02            | 11.04±1.18       | 29.05±0.75        | 150.3±5.72         | 2.72±0.02     | 3.44±0.22        | 0.73±0.02     | 101.8±1.30            |
| F3    | 0.74±0.07           | 0.86±0.03            | 14.81±1.18       | 28.17±0.57        | 150.4±4.75         | 2.70±0.01     | 3.5±0.35         | 0.67±0.05     | 103.3±1.10            |
| F4    | 0.76±0.06           | 0.86±0.01            | 11.52±1.18       | 29.51±0.46        | 150.4±4.72         | 2.71±0.01     | 3.41±0.41        | 0.55±0.07     | 101.8±1.72            |
| F5    | 0.66±0.02           | 0.76±0.05            | 13.33±1.18       | 27.34±0.54        | 150.5±4.58         | 2.73±0.02     | 3.42±0.25        | 0.72±0.09     | 101.3±1.79            |
| F6    | 0.76±0.03           | 0.86±0.06            | 11.52±1.18       | 27.75±0.23        | 150.4±5.44         | 2.70±0.01     | 3.75±0.44        | 0.82±0.03     | 102.9±1.09            |
| F7    | 0.66±0.02           | 0.74±0.02            | 10.0±1.18        | 27.34±0.86        | 150.5±4.28         | 2.71±0.03     | 3.27±0.2         | 0.69±0.01     | 102.7±1.16            |
| F8    | 0.71±0.06           | 0.83±0.01            | 14.25±1.18       | 26.95±0.67        | 150.75±3.59        | 2.73±0.03     | 3.35±0.44        | 0.66±0.04     | 103.7±0.91            |
| F9    | 0.68±0.05           | 0.76±0.04            | 10.34±1.18       | 26.56±0.45        | 150.3±4.61         | 2.68±0.03     | 3.47±0.22        | 0.59±0.05     | 101.8±0.36            |

(n=6)

### Table 6: In vitro dissolution of factorial batches of sildenafil citrate 100 dispersible tablets

| Time (min) | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 |
|------------|----|----|----|----|----|----|----|----|----|
| 0          | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| 2          | 82.0±0.59   | 84.1±0.78 | 86.3±0.98 | 87.3±0.81 | 83.8±1.19 | 88.6±1.25 | 84.3±0.45 | 89.3±1.19 | 90.5±0.98 |
| 4          | 95.2±1.37   | 95.7±1.19 | 96.7±0.81 | 97.5±0.59 | 97.1±0.59 | 97.4±0.67 | 97.8±0.67 | 97.9±0.45 | 98.0±0.22 |
| 6          | 97.6±0.81   | 98.4±0.60 | 97.8±1.03 | 98.7±0.39 | 98.0±0.81 | 98.7±0.45 | 98.2±1.03 | 98.7±0.45 | 99.1±0.22 |
| 8          | 98.9±0.39   | 98.6±0.39 | 98.4±0.90 | 98.8±0.98 | 99.1±0.22 | 99.3±0.39 | 99.3±0.39 | 99.1±0.22 | 99.6±0.19 |
| 10         | 99.2±0.22   | 99.9±0.39 | 99.0±0.36 | 99.2±0.45 | 99.6±0.22 | 99.5±0.59 | 99.6±0.59 | 99.3±0.32 | 99.6±0.07 |
| 15         | 99.3±0.39   | 99.20±0.22 | 99.6±0.22 | 100.0±0.22 | 99.7±0.78 | 100.1±0.39 | 100.0±0.90 | 99.7±0.39 | 100.1±0.67 |
| 20         | 99.6±0.22   | 99.70±0.39 | 99.6±0.59 | 100.4±0.22 | 100.1±0.39 | 100.6±0.81 | 100.6±0.45 | 100.2±0.45 | 100.4±0.59 |

(n=6)

Full and reduced model for dispersion time

\[ DT = 75.910 - (4.900 X_1) - (6.900 X_2) + (0.033X_1X_2) + (2.833X_1^2) + (0.750X_2^2) \]

When effervescence agent and croscarmellose sodium was increase dispersion time decrease. From the 3D plot (fig. 3A) and the regression coefficient values of factors, it was concluded that croscarmellose sodium give more significant than effervescence agent. Both the effervescence agent and croscarmellose sodium showed significant effect in the model. Interaction and nonlinearity was not observed. For dispersion time, the significance levels of the coefficients b1, b2, and b12 were found to be 0.079, 0.098 and 0.440 respectively, so they were omitted from the full model to generate a reduced model. The coefficients b1, b2, and b12 significant at P<0.05; hence they were retained in the reduced model. The reduced model for drug dispersion time,

\[ DT = 75.910 - (4.900 X_1) - (6.900 X_2) \]
### Table 7: Runs and measured responses of 3² factorial design batches

| Batch | Amount of effervescent agent ($X_1$) | Amount of croscarmellose sodium ($X_2$) | Dispersion time (Sec) ($Y_1$) | Wetting time (Sec) ($Y_2$) |
|-------|-------------------------------------|----------------------------------------|-------------------------------|---------------------------|
| F₁    | -1                                  | -1                                     | 92.6±3.07                     | 23.0±0.45                 |
| F₂    | 0                                   | -1                                     | 84.4±1.35                     | 20.66±0.87                |
| F₃    | 1                                   | -1                                     | 80.0±1.41                     | 16.66±0.87                |
| F₄    | -1                                  | 0                                      | 79.2±1.16                     | 15.33±0.59                |
| F₅    | 0                                   | 0                                      | 76.6±1.62                     | 14.66±0.32                |
| F₆    | 1                                   | 0                                      | 72.0±1.41                     | 12.66±0.52                |
| F₇    | -1                                  | 1                                      | 76.4±2.05                     | 11.66±0.78                |
| F₈    | 0                                   | 1                                      | 72.4±1.01                     | 10.66±0.85                |
| F₉    | 1                                   | 1                                      | 68.8±1.60                     |                            |

Factors and the levels in the design:
- Independent variables: Low (-1), Medium (0), High (1)
- Amount of effervescent agent ($X_1$): 30, 45, 60
- Amount of Croscarmellose sodium ($X_2$): 450, 600, 750

(n=6)

### Table 8: Results of the ANOVA for dependent variables

| Source of variation | DF | SS      | MS      | F value | P value |
|---------------------|----|---------|---------|---------|---------|
| Dispersion time     |    |         |         |         |         |
| Regression          | 5  | 448.030 | 89.610  | 31.380  | 0.009   |
| Residual            | 3  | 008.570 | 002.860 |         |         |
| Total               | 8  | 456.600 | 057.074 |         |         |
| Wetting time        |    |         |         |         |         |
| Regression          | 5  | 159.550 | 031.910 | 101.570 | 0.002   |
| Residual            | 3  | 000.940 | 000.310 |         |         |
| Total               | 8  | 160.500 | 031.910 |         |         |

### Table 9: Summary of regression output of factors for measured responses

| Responses | Model | Coefficient of regression parameters | b₀ | b₁ | b₂ | b₁₁ | b₂₂ | b₁₂ | R² |
|-----------|-------|-------------------------------------|----|----|----|-----|-----|-----|----|
| Dispersion time | Full | 75.910                             | -4.900 | -6.900 | +0.033 | 2.833 | 0.750 | 0.981 |
|            | Reduced | 75.910                           | -4.900 | -6.900 | -   | -   | -   | -   |
| Wetting time  | Full | 15.402                             | -1.335 | -4.890 | 0.222 | 1.557 | 0.333 | 0.994 |
|            | Reduced | 15.402                         | -1.335 | -4.890 | -   | 1.557 | -   | -   |

**Full and reduced model for wetting time**

\[
WT = 15.402 - (1.335X_1) - (4.890X_2) + (0.222X_1X_2) + (1.557X_1^2) - (0.333X_2^2)
\]

From the 3D plot (Fig. 3B) and the regression coefficient values of factors, it was concluded that when effervescent agent and croscarmellose sodium was increased, the time of wetting time decreased. The results also indicated that the croscarmellose sodium was given a more significant effect on wetting time. Both the effervescent agent and croscarmellose sodium showed significant effect in the model. Interaction and nonlinearity was not observed.

For wetting time, the significance levels of the coefficients $b_{11}$ and $b_{12}$ were found to be $P=0.615$ and $0.321$ respectively, so they were omitted from the full model to generate a reduced model. The coefficients $b_1$, $b_2$, and $b_{12}$ were found to be significant at $P<0.05$; hence, it was retained in the reduced model [31]. The reduced model for wetting time is:

\[
WT = 15.402 - (1.335X_1) - (4.890X_2) + (1.557X_1^2)
\]

![Fig. 3A: 3D plot showing the effect of effervescent agent and Croscarmellose sodium on dispersion time](image-url)
Formulation and evaluation of check point batch

A checkpoint batch was designed accordance to the desirability function as shown in fig. 3C. To validate the evolved mathematical, a checkpoint batch was prepared and evaluated under the same conditions as outlined for the other batches. The response data was compared with predicted data. The application of desirability function gives possibility to predict the optimum levels for the independent variables. In this study, the following constraints were used for the selection of an optimized batch: Dispersion time was 70 to 72 s and wetting time was 10 to 12 s. Desirability plot showed that prediction is 1 when 743.44 mg of effervescence agents and 47.25 mg of Croscarmellose sodium are used. So, checkpoint batch was formulated and validated by using same amount of effervescence agents and Croscarmellose sodium. Results of validation of checkpoint batch are shown in table 10. Results of in vitro dispersion time and wetting time showed no significance difference between predicted value and actual value, which suggests that the evolved models may be used for theoretical prediction of responses within the factor space. After short-term stress stability studies check point batch initial in vitro release profile was compared using similarity factor, ($f_2$) value which was found to be 89.50±1.52%. There is no significant difference in similarity factor. Other stability evaluation parameter after 3 mo was shown in table 11. No significant changes were observed in any parameters during the study period, thus it could be concluded that formulation was stable.

Table 10: Formulation of checkpoint batch and comparison with predicted value

| Independent variable       | Dispersion time (sec) | Wetting time (sec) |
|----------------------------|-----------------------|--------------------|
|                            | Predicted value       | Actual value       | Predicted value | Actual value |
| X1 (Effervescence agents)  | 71.27                 | 73±0.45            | 11.90           | 12±46        |
| X2 (Croscarmellose sodium) | 743.44 mg             |                     | 47.25 mg        |              |

(n=6)

Table 11: Evaluation of checkpoint batch after stability study

| S. No. | Parameters | Initial                  | After 3 mo   |
|--------|------------|--------------------------|--------------|
| 1      | Appearance | Light orange colour,     | No change    |
| 2      | Hardness (Kg/cm²) | 3.3±0.44            | 3.4±0.22     |
| 3      | Friability | 0.666 %                  | 0.676 %      |
| 4      | Dispersion time (Sec) | 72.4±1.01         | 72.8±1.30    |
| 5      | Wetting time (Sec) | 11.66±0.57          | 12.0±0.10    |

(n=6)
CONCLUSION
The objective of the present investigation was to formulate, evaluate and optimize the of sildenafil citrate 100 mg dispersible tablets to achieve quick disintegration and fast release of the drug. Kyron T134 was used as taste masking agent that showed highest % of drug loading and test masking. These formulations were evaluated for the parameters like drug excipient compatibility study, thickness, hardness, weight variation, % friability, disintegration test, in vitro drug release and accelerated stability studies. Based on preliminary results, the amount of effervescence agents (X1) and the amount of Crosscarmellose sodium (X2) were chosen as independent variables in 3² full factorial design, while dispersion time and wetting time of the tablets were taken as dependent variables. Multiple linear regression analysis, ANOVA and graphical representation of the influence of factor by 3D plots were performed using Sigma plot 11.0. From the results of multiple regression analysis, it was found that both factors had significant influence on all dependent variables. A Check point batch was design according to the results of desirability value and evaluated for all the parameter. The results of comparison of predicted response and obtained response were found in good agreement. The formulation was found to be stable during accelerated stability study.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
All authors have contributed equally.

CONFLICT OF INTERESTS
Declared none

REFERENCES
1. Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: an overview. J Chem Pharm Res 2009;1:163-77.
2. Paramita D, Arnabi G. Wafer: an innovative advancement of orodispersible films. Int J Appl Pharm 2016;8:1-7.
3. Sharma S, Lewis S. Taste masking technologies: a review. Int J Pharm Pharm Sci 2010;2:6-13.
4. Nanda A, Kandrapo R, Garg S. An update on taste masking technologies for oral pharmaceuticals. Indian J Pharm Sci 2002;64:10-7.
5. Bokell M, Allen MJ, Ballard SA. Sildenafil: an orally active type 5 cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52
6. Iodell CT Jr, Morey TE, Lobato EB, Aranda JM Jr, Staples ED, Schofield RS. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007;83:68-71.
7. Kumar RG, Sanghvi L. Optimization techniques: an overview for formulation development. Asian J Pharm Res 2015;5:217-21.
8. Nazmi M, Islam SMA, Bhuiyan MA, Reza MS. Effect of super disintegrants and their mode of incorporation on disintegration time and release profile of carbamazepine from an immediate-release tablet. J Appl Pharm Sci 2013;3:80-4.
9. Fatima SD, Komal S, Sholapur GN, Nanjundaswamy NG, Sajanar VM. Design, optimization and evaluation of chewable tablets of clarithromycin using ion exchange resins. Indian J Pharm Sci 2016;78:818-26.
10. Faham A, Marechal D, Chenevier P. Orodispersible tablets containing fexofenadine, US Patent 6723348 B2; 2004.
11. Puttewar TY. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. J King Saud Univ 2010;22:229-40.
12. Anand V, Kandrapo R, Garg S. Preparation and evaluation of taste-masked orally disintegrating tablets of prednisolone. Asian J Pharm Sci 2007;6:227-38.
13. Al dhahir, RK Al-kotaji. Formulation of orally disintegrating tablets of cinnarizine by using direct compression method. Int J Appl Pharm 2019;11:27-38.
14. Patel RP, Patel JK, Rajput GC, Thakor RS. Formulation and evaluation of mouth dissolving tablets of cinnarizine. Indian J Pharm Sci 2010;72:522-5.
15. Yadav K, Yadav D, Srivastava A. Evaluation of hydrophilic, hydrophobic and waxy matrix excipients for sustained release tablets of venlafaxine hydrochloride. Drug Dev Ind Pharm 2013;39:1197-206.
16. Khar RK, Mohapatra S, Barik BB. Design and characterization of controlled release matrix tablets of Zidovudine. Asian J Pharm Clin Res 2009;2:54-61.
17. Madgulkar AR. Formulation and optimization of sustained release tablets of venlafaxine resinates using response surface methodology. Indian J Pharm Sci 2009;71:387-94.
18. Lakade SH, Bhalekar MR. Formulation and evaluation of sustained release matrix tablet of anti-anginal drug influence of combination of hydrophobic and hydrophilic matrix former. Res J Pharm Technol 2008;1:410-4.
19. Puttewar TY. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. King Saud Univ 2010;22:229-40.
20. Anand V, Kandrapo R, Garg S. Preparation and evaluation of taste-masked orally disintegrating tablets of prednisolone. Asian J Pharm Sci 2007;6:227-38.
21. Bokel S. Optimization techniques in pharmaceutical statistics. Practical and clinical Applications. 3rd ed. New York: Marcel Dekker; 1997.
22. Anthony NA. Pharmaceutical experimental design and interpretation. 2nd ed. Taylor and Francis Group; 2006.
23. Lionberger RA, Lee SL, Lee L. Quality by design: concepts for ANDAs. Adv Appl Pharm Sci J 2008;10:268-76.
24. Guideline ICH. Stability testing guidelines: stability testing of new drug substances and products. ICH Q1A (R2) (CPMP/ICH/2736/99); 1999.
25. Singh S. Stability testing during product development. In: Jain NK, Pharmaceutical product development. CBS publisher and distributors India; 2000. p. 272-93.
26. Bajaj S, Singhla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci 2012;2:Suppl 3:129-38.
27. Vogel AI. Vogel's textbook of quantitative chemical analysis. 5th ed. Jeffrey GH, Bassett J, Mendenhall J, Denney R. editors; 1999. p. 220-5.
28. Nagar P, Singh K, Chauhan I, Madhu V, Yasir M, Khan A, et al. Orally disintegrating tablets: formulation, preparation, techniques, and evaluation. J Appl Pharm Sci 2011;1:43-45.
29. Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design. New York: Marcel Dekker; 1999. p. 191-8.
30. Anthony NA. Pharmaceutical experimental design and interpretation. 2nd ed. Taylor and Francis Group; 2006.
31. Khanam N, Alam MI, MD Yusuf Ali, QMAI Siddiqui, A Ur Rahman. A review on optimization of drug delivery system with experimental designs. Int J Appl Pharm 2018;10:7-12.